

102.166A

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

S. BAY et al

Serial No.: 09/049,847 Filed: March 27, 1998

For: MULTIPLE...USE THEREOF

T. Bhatti

Group: 162

600 Third Avenue New York N.Y. 100

December 6, 2001

RESPONSE

Asst. Commissioner for Patents Washington, D.C. 20231

Sir:

Responsive to the office action of November 6, 2001, Applicants request reconsideration of the application in view of the remarks presented herein.

The claims in the application are claims 29 to 32, 35, 40, 42 to 44, 46 and 47, all other claims having been cancelled.

The Examiner has indicated that claim 29 is drawn to a plurality of patentably distinct species and their use and has required Applicants to elect one of the generic members of the Markush group indicated in the office action and a single compound within the elected Markush generic group.

Applicants respectfully traverse this requirement since the present application is a RCE and the original application received three office actions on the merits with the present claims and it is deemed that there is but a single invention present. It is not

De 6 200/

GAU/162

known why the election is being made at this time in view of the circumstances. However, in order to be fully in compliance with the office action, Applicants elect with traverse the generic B4-T4-M. With respect to the election of species, Applicants elect again with traverse the B tumor antigen which is Tn antigen and the T antigen is sequence 103 to 115 from protein VP1 of the poliovirus type I which is Example 2 of the application.

Since the first office action in the RCE was merely a restriction requirement, a prompt examination on the merits is requested.

Respectfully submitted, Bierman, Muserlian and Lucas

By:

Charles A. Muserlian #19,683 Attorney for Applicants Tel.# (212) 661-8000

CAM:ds

Encl.: Return receipt postcard